These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22622825)

  • 41. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
    Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
    Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
    Chen HH; Chang PC; Chen C; Chan MH
    Pharmacol Rep; 2018 Aug; 70(4):668-676. PubMed ID: 29909247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroprotective effect of curcumin-I in copper-induced dopaminergic neurotoxicity in rats: A possible link with Parkinson's disease.
    Abbaoui A; Chatoui H; El Hiba O; Gamrani H
    Neurosci Lett; 2017 Nov; 660():103-108. PubMed ID: 28919537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of BDNF/TrkB signaling in the effect of diphenyl diselenide on motor function in a Parkinson's disease rat model.
    Sampaio TB; Pinton S; da Rocha JT; Gai BM; Nogueira CW
    Eur J Pharmacol; 2017 Jan; 795():28-35. PubMed ID: 27915043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
    Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
    J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Myricetin reduces 6-hydroxydopamine-induced dopamine neuron degeneration in rats.
    Ma ZG; Wang J; Jiang H; Liu TW; Xie JX
    Neuroreport; 2007 Jul; 18(11):1181-5. PubMed ID: 17589323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
    Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
    Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-administration of BAX-inhibiting peptides decrease the loss of the nigral dopaminergic neurons in rats.
    Ma C; Pan Y; Yang Z; Meng Z; Sun R; Wang T; Fei Y; Fan W
    Life Sci; 2016 Jan; 144():113-20. PubMed ID: 26612350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease.
    Anastasía A; Torre L; de Erausquin GA; Mascó DH
    J Neurochem; 2009 May; 109(3):755-65. PubMed ID: 19245661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
    Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
    J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model.
    Park HJ; Lim S; Joo WS; Yin CS; Lee HS; Lee HJ; Seo JC; Leem K; Son YS; Kim YJ; Kim CJ; Kim YS; Chung JH
    Exp Neurol; 2003 Mar; 180(1):93-8. PubMed ID: 12668152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
    Boshoff EL; Fletcher EJR; Duty S
    Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
    Andringa G; van Oosten RV; Unger W; Hafmans TG; Veening J; Stoof JC; Cools AR
    Eur J Neurosci; 2000 Aug; 12(8):3033-43. PubMed ID: 10971644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Propolis as A Potential Disease-Modifying Strategy in Parkinson's Disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model.
    Gonçalves VC; Pinheiro DJLL; de la Rosa T; de Almeida AG; Scorza FA; Scorza CA
    Nutrients; 2020 May; 12(6):. PubMed ID: 32466610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
    Mazzocchi M; Goulding SR; Morales-Prieto N; Foley T; Collins LM; Sullivan AM; O'Keeffe GW
    Brain Behav Immun; 2022 May; 102():151-160. PubMed ID: 35217173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Curcumin I mediates neuroprotective effect through attenuation of quinoprotein formation, p-p38 MAPK expression, and caspase-3 activation in 6-hydroxydopamine treated SH-SY5Y cells.
    Meesarapee B; Thampithak A; Jaisin Y; Sanvarinda P; Suksamrarn A; Tuchinda P; Morales NP; Sanvarinda Y
    Phytother Res; 2014 Apr; 28(4):611-6. PubMed ID: 23857913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease.
    Sasaki T; Liu K; Agari T; Yasuhara T; Morimoto J; Okazaki M; Takeuchi H; Toyoshima A; Sasada S; Shinko A; Kondo A; Kameda M; Miyazaki I; Asanuma M; Borlongan CV; Nishibori M; Date I
    Exp Neurol; 2016 Jan; 275 Pt 1():220-31. PubMed ID: 26555088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease.
    Winter C; Hosmann K; Harnack D; Meissner W; Paul G; Morgenstern R; Kupsch A
    Synapse; 2006 Jul; 60(1):69-80. PubMed ID: 16598703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.